{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T23:31:01Z","timestamp":1768001461858,"version":"3.49.0"},"reference-count":43,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2005,3,8]],"date-time":"2005-03-08T00:00:00Z","timestamp":1110240000000},"content-version":"vor","delay-in-days":3841,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cytometry"],"published-print":{"date-parts":[[1994,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Expression of the multidrug\u2010resistant (MDR) phenotype was investigated in acute leukemia using a monoclonal antibody (HYB\u2010241) directed against a cell surface epitope of the 180 kd P\u2010glycoprotein (gp180) by flow cytometric analysis of clinical samples. Samples from sixtyfour patients were tested (37 with acute myelocytic leukemia, 20 with acute lymphocytic leukemia, and 7 with blastic chronic myelocytic leukemia). A D value (derived from Kolmogorov\u2010Smirnov test) greater than 0.15 was considered positive (+). Eight of 32 newly diagnosed patients were positive for gp180 compared with 22 of 32 relapsed\/refractory (R\/R) patients (<jats:italic>P<\/jats:italic> &lt; 0.001). Of the new patients, vinca\/anthracycline\u2010based induction therapy failed in 3\/6 gp180(+) and 5\/18 gp180(\u2212) patients. In the R\/R group, 15\/16 gp180(+) and 3\/6 gp180(\u2212) patients failed to achieve complete remission (<jats:italic>P<\/jats:italic> &lt; 0.05). In vitro drug accumulation studies performed with verapamil failed to show a correlation with clinical response. However, in a subset of patients, a striking correlation (r = .97, <jats:italic>P<\/jats:italic> = .001) was noted between the presence of gp180 as determined by the D value and the functional activity of the P\u2010glycoprotein as expressed by increased daunorubicin accumulation in the presence of verapamil. The results suggest that (1) newly diagnosed patients can express gp180, (2) P\u2010glycoprotein is expressed in 69% of R\/R patients, (3) response in R\/R patients is effected by the presence of gp180, and (4) expression of gp180 is highly correlated with its function as a drug\u2010efflux pump in a subset of the patients studied. The complexity of clinical drug resistance is underscored by the finding that the MDR model is not applicable to all cases. In such instances, other mechanisms may play a predominant role. \u00a9 1994 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/cyto.990170111","type":"journal-article","created":{"date-parts":[[2005,6,30]],"date-time":"2005-06-30T20:46:27Z","timestamp":1120164387000},"page":"84-93","source":"Crossref","is-referenced-by-count":26,"title":["Flow cytometric determination of the multidrug\u2010resistant phenotype in acute leukemia"],"prefix":"10.1002","volume":"17","author":[{"given":"Peter","family":"Maslak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanna","family":"Hegewisch\u2010Becker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loren","family":"Godfrey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Andreeff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,6,23]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"2070","article-title":"Altered surface membrane glycoproteins in vinca alkaloid\u2010resistant human leukemic lymphoblasts","volume":"39","author":"Beck WT","year":"1979","journal-title":"Cancer Res"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V77.4.818.818"},{"key":"e_1_2_1_4_2","first-page":"1174","article-title":"Cellular resistance to actinomycin D in clinical hamster cells in vitro: Cross resistance, radioautographic and cytogenetic studies","volume":"30","author":"Biedler JL","year":"1970","journal-title":"Cancer Res"},{"key":"e_1_2_1_5_2","first-page":"87","article-title":"Mechanism of multidrug resistance","volume":"948","author":"Bradley G","year":"1988","journal-title":"Biochim Biophys Acta"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1989.tb04315.x"},{"key":"e_1_2_1_7_2","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood.V79.2.473.473","article-title":"Clinical significance of multi\u2010drug resistance p\u2010glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis","volume":"79","author":"Campos L","year":"1992","journal-title":"Blood"},{"key":"e_1_2_1_8_2","first-page":"89","article-title":"Ara\u2010C metabolism: Implications for drug resistance and drug interactions","volume":"66","author":"Chabner BA","year":"1979","journal-title":"Bull Cancer"},{"key":"e_1_2_1_9_2","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1182\/blood.V69.6.1551.1551","article-title":"Acute myelogenous leukemia: Recent advances in therapy","volume":"69","author":"Champlin R","year":"1987","journal-title":"Blood"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(91)90141-K"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V80.11.2735.2735"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.2.695"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.4.415"},{"key":"e_1_2_1_14_2","first-page":"3595","article-title":"Multifactorial resistance to adriamycin: Relationship of DNA repair, glutathione transferase activity, drug efflux, and p\u2010glycoprotein in cloned cell lines of adriamycin\u2010sensitive and resistant P388 leukemia","volume":"48","author":"Deffie AM","year":"1988","journal-title":"Cancer"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V80.11.2729.2729"},{"key":"e_1_2_1_16_2","first-page":"3002","article-title":"Reduced drug accumulation in multiple drug\u2010resistant KB carcinoma cell lines","volume":"45","author":"Fojo AT","year":"1985","journal-title":"Cancer Res"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.83.20.7785"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19890415)63:8<1534::AID-CNCR2820630813>3.0.CO;2-N"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0005-2736(76)90160-7"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/jss.400040412"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/316820a0"},{"key":"e_1_2_1_22_2","first-page":"459","article-title":"Uptake and phosphorylation of cytosine arabinoside by normal and leukemia human blood cells in vitro","volume":"29","author":"Kessel D","year":"1969","journal-title":"Cancer Res"},{"key":"e_1_2_1_23_2","first-page":"1768","article-title":"Flow cytometric monitoring of cellular anthracycline accumulation in murine leukemic cells","volume":"46","author":"Krishan A","year":"1986","journal-title":"Cancer Res"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.990080311"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1990.tb02533.x"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19900901)66:5<868::AID-CNCR2820660510>3.0.CO;2-Z"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.1040830114"},{"key":"e_1_2_1_28_2","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1200\/JCO.1993.11.9.1652","article-title":"Phase I\/II trial of cyclosporine as a chemotherapy resistance modifier in acute leukemia","volume":"11","author":"List AF","year":"1990","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V78.3.586.586"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1989.tb07716.x"},{"key":"e_1_2_1_31_2","first-page":"3959","article-title":"Mechanisms of multidrug resistance in HL\u201060 cells: Evidence that a surface membrane protein distinct from p\u2010glycoprotein contributes to reduced cellular accumulation of drug","volume":"48","author":"McGarth T","year":"1988","journal-title":"Cancer Res"},{"key":"e_1_2_1_32_2","first-page":"3209","article-title":"Characterization of monoclonal antibodies recognizing a Mr 180,000 p\u2010glycoprotein: Differential expression of the Mr 180,000 and Mr 170,000 p\u2010glycoprotein in multidrug\u2010resistant human tumor cells","volume":"49","author":"Meyers MB","year":"1989","journal-title":"Cancer Res"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.1.17"},{"key":"e_1_2_1_34_2","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1182\/blood.V81.11.3083.3083","article-title":"Unusual immunophenotype combination in acute myelogenous leukemia","volume":"81","author":"Reading C","year":"1993","journal-title":"Blood"},{"key":"e_1_2_1_35_2","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1182\/blood.V74.4.1388.1388","article-title":"Expression of the MDR\u20101\/p\u2010170 gene in patients with acute lymphoblastic leukemia","volume":"74","author":"Rothenberg M","year":"1989","journal-title":"Blood"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/0145-2126(90)90141-U"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1990.tb04346.x"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.11.1730"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1990.tb02650.x"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1989.309"},{"key":"e_1_2_1_41_2","first-page":"2905","article-title":"Circumvention of vincristine and adriamycin resistance in vitro and in vivo by calcium influx blockers","volume":"43","author":"Tsuruo T","year":"1983","journal-title":"Cancer Res"},{"issue":"1","key":"e_1_2_1_42_2","first-page":"337a","article-title":"Immunophenotypic heterogeneity of leukemia cells in AML at diagnosis and after chemotherapy","volume":"76","author":"Wormann B","year":"1990","journal-title":"Blood"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.1177\/25.7.894009"},{"key":"e_1_2_1_44_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4613-1601-5_1"}],"container-title":["Cytometry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcyto.990170111","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cyto.990170111","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T00:52:26Z","timestamp":1698108746000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cyto.990170111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1994,9]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1994,9]]}},"alternative-id":["10.1002\/cyto.990170111"],"URL":"https:\/\/doi.org\/10.1002\/cyto.990170111","archive":["Portico"],"relation":{},"ISSN":["0196-4763","1097-0320"],"issn-type":[{"value":"0196-4763","type":"print"},{"value":"1097-0320","type":"electronic"}],"subject":[],"published":{"date-parts":[[1994,9]]}}}